Gerald McMahon
Impact in
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
- Protease and Inhibitor Mechanisms
- Immunology and Allergy top 0.5%
- Cell Adhesion Molecules Research
Papers in
-
- Angiogenesis and VEGF in Cancer 25
- PI3K/AKT/mTOR signaling in cancer 7
- DNA Repair Mechanisms 5
-
- Cancer, Hypoxia, and Metabolism 15
- Carcinogens and Genotoxicity Assessment 6
- Co-authors
- Cho Tang (14 shared papers)Li Sun (8 shared papers)Shigeyoshi Itohara (1 shared paper)Thiennu H. Vu (1 shared paper)Takeshi Itoh (1 shared paper)Rolf A. Brekken (1 shared paper)Gabriele Bergers (1 shared paper)Douglas Hanahan (1 shared paper)
- Journals
- Proceedings of the National Academy of Sciences (5 papers)Blood (4 papers)Journal of Medicinal Chemistry (4 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)The FASEB Journal (2 papers)
- Partner nations
- United StatesJapanGermany
In The Last Decade
Gerald McMahon
79 papers receiving 11.6k citations
Gerald McMahon's Hit Papers
Peers
Comparison fields: 5 of 142
- Cancer Research 2.5k
- Immunology and Allergy 715
- Oncology 2.7k
- Molecular Biology 6.4k
- Hematology 824
Countries citing papers authored by Gerald McMahon
This map shows the geographic impact of Gerald McMahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald McMahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald McMahon more than expected).
Fields of papers citing papers by Gerald McMahon
This network shows the impact of papers produced by Gerald McMahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald McMahon. The network helps show where Gerald McMahon may publish in the future.
Co-authors
The 25 scholars most cited alongside Gerald McMahon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Hit paper breakdown → | 2000 | 2230 |
| 2 | Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors Hit paper breakdown → | 1997 | 961 |
| 3 | SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Hit paper breakdown → | 1999 | 885 |
| 4 | Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids Hit paper breakdown → | 1995 | 599 |
| 5 | 1998 | 430 | |
| 6 | 2000 | 403 | |
| 7 | SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. | 2000 | 401 |
| 8 | 2002 | 359 | |
| 9 | 2005 | 312 | |
| 10 | Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. | 2001 | 280 |
| 11 | Flk-1 as a target for tumor growth inhibition. | 1996 | 279 |
| 12 | Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. | 1999 | 277 |
| 13 | 2000 | 269 | |
| 14 | SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. | 2003 | 226 |
| 15 | Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. | 2003 | 223 |
| 16 | 1999 | 213 | |
| 17 | 1996 | 208 | |
| 18 | 2001 | 179 | |
| 19 | 2000 | 176 | |
| 20 | 2010 | 148 |
About Gerald McMahon
Gerald McMahon is a scholar working on Molecular Biology, Cancer Research, Oncology, Immunology and Organic Chemistry, having authored 80 papers that have together received 11.9k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (25 papers), Cancer, Hypoxia, and Metabolism (15 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), HER2/EGFR in Cancer Research (6 papers), Bioactive Compounds and Antitumor Agents (6 papers), Mast cells and histamine (6 papers), Carcinogens and Genotoxicity Assessment (6 papers) and DNA Repair Mechanisms (5 papers). The work is most often cited by research in Cancer Research (2.5k citations), Immunology and Allergy (715 citations), Oncology (2.7k citations), Molecular Biology (6.4k citations) and Hematology (824 citations). Gerald McMahon has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Cho Tang, Li Sun, Shigeyoshi Itohara, Thiennu H. Vu, Takeshi Itoh, Rolf A. Brekken, Gabriele Bergers, Douglas Hanahan, Zena Werb and Philip E. Thorpe. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood, Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and The FASEB Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.